Davis Polk Advises Centogene N.V. on Its Initial Public Offering

Davis Polk advised Centogene N.V. on its $56 million initial public offering of 4,000,000 of its common shares. In addition, Centogene has granted the underwriters a 30-day option to purchase up to an additional 600,000 common shares. The common shares are listed on the Nasdaq Global Market under the symbol “CNTG.” 

Based in Rostock, Germany, Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company’s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using their knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. Centogene has developed a global proprietary rare disease platform, which includes epidemiologic, phenotypic and genetic data that reflects a global population, and also a biobank of patients’ blood samples, which can aid the identification of patients and improve their pharmaceutical partners’ ability to bring orphan drugs to the market.

The Davis Polk corporate team included partners Leo Borchardt and Richard D. Truesdell Jr. and associates Andrew Rowe and Grace M. Cao. The tax team included partner Michael Mollerus and associate Tomislava Dragicevic. The intellectual property and technology team included partner David R. Bauer and associate Jay Frankel. The executive compensation team included partner Veronica M. Wissel and associate Justin Alexander Kasprisin. Members of the Davis Polk team are based in the London and New York offices.